PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 6071人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1255096, encodeId=232d125509661, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nat Med：不适合顺铂治疗的高风险尿路上皮癌患者的新辅助PD-L1加CTLA-4阻断疗法, objectType=article, longId=202749, objectId=c7e3202e494d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7e3202e494d, replyNumber=0, likeNumber=71, createdTime=2020-11-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7e3202e494d, moduleTitle=Nat Med：不适合顺铂治疗的高风险尿路上皮癌患者的新辅助PD-L1加CTLA-4阻断疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7e3202e494d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255095, encodeId=c41a1255095c7, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者, objectType=article, longId=202660, objectId=e6f9202660eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6f9202660eb, replyNumber=0, likeNumber=57, createdTime=2020-10-31, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6f9202660eb, moduleTitle=PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6f9202660eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255094, encodeId=495712550946c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nat Cell Biol：到底是促癌还是抑癌？PD-L1还有不为人知的一面, objectType=article, longId=202151, objectId=7997202151ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7997202151ff, replyNumber=0, likeNumber=89, createdTime=2020-10-17, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7997202151ff, moduleTitle=Nat Cell Biol：到底是促癌还是抑癌？PD-L1还有不为人知的一面, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7997202151ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255093, encodeId=75481255093f3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nat Commun：研究定义了PD-L1阴性ER阳性乳腺癌患者的新型免疫特征, objectType=article, longId=201763, objectId=dcb3201e63ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcb3201e63ed, replyNumber=0, likeNumber=69, createdTime=2020-10-07, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcb3201e63ed, moduleTitle=Nat Commun：研究定义了PD-L1阴性ER阳性乳腺癌患者的新型免疫特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcb3201e63ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255092, encodeId=97a51255092b9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=辉瑞投资基石药业2亿美元，获得PD-L1大陆**商业权利, objectType=article, longId=201425, objectId=e5ba20142593, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5ba20142593, replyNumber=0, likeNumber=80, createdTime=2020-10-02, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5ba20142593, moduleTitle=辉瑞投资基石药业2亿美元，获得PD-L1大陆**商业权利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5ba20142593)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255091, encodeId=2a3812550912c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle= Lancet oncol：PD-L1抑制剂Durvalumab±曲美单抗治疗转移性尿路上皮癌, objectType=article, longId=201131, objectId=a81a2011316b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a81a2011316b, replyNumber=0, likeNumber=115, createdTime=2020-09-25, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a81a2011316b, moduleTitle= Lancet oncol：PD-L1抑制剂Durvalumab±曲美单抗治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a81a2011316b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255090, encodeId=fc2f125509050, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=T药+白蛋白紫杉醇一线治疗三阴乳腺癌：PD-L1阳性人群OS获益显著，亚洲人群不佳, objectType=article, longId=201088, objectId=5c682010884c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c682010884c, replyNumber=0, likeNumber=61, createdTime=2020-09-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c682010884c, moduleTitle=T药+白蛋白紫杉醇一线治疗三阴乳腺癌：PD-L1阳性人群OS获益显著，亚洲人群不佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c682010884c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255089, encodeId=4dcc125508983, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Br J Cancer：FOXP3和PD-L1或可成为化生性乳腺癌的潜在治疗靶标, objectType=article, longId=201081, objectId=876620108126, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=876620108126, replyNumber=0, likeNumber=63, createdTime=2020-09-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=876620108126, moduleTitle=Br J Cancer：FOXP3和PD-L1或可成为化生性乳腺癌的潜在治疗靶标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=876620108126)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255088, encodeId=fac21255088c4, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nat Cell Biol：不仅仅是免疫检查点，Nature子刊揭示PD-L1在肿瘤焦亡中的新机制, objectType=article, longId=200962, objectId=1440200962ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1440200962ed, replyNumber=0, likeNumber=67, createdTime=2020-09-22, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1440200962ed, moduleTitle=Nat Cell Biol：不仅仅是免疫检查点，Nature子刊揭示PD-L1在肿瘤焦亡中的新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1440200962ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255087, encodeId=8bbf125508e15, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=皮下注射PD-L1在中国申报上市，拟优先审评, objectType=article, longId=200936, objectId=f3b920093688, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3b920093688, replyNumber=0, likeNumber=74, createdTime=2020-09-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3b920093688, moduleTitle=皮下注射PD-L1在中国申报上市，拟优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3b920093688)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255086, encodeId=bbe81255086e0, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nat Commun：抗GARP:TGF-β1单抗能克服PD-1/PD-L1抑制剂耐药性, objectType=article, longId=200773, objectId=f5e6200e73e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5e6200e73e3, replyNumber=0, likeNumber=67, createdTime=2020-09-18, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5e6200e73e3, moduleTitle=Nat Commun：抗GARP:TGF-β1单抗能克服PD-1/PD-L1抑制剂耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5e6200e73e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255085, encodeId=25241255085e2, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=康宁杰瑞PD-L1/CTLA-4双特异性抗体获FDA孤儿药资格认定, objectType=article, longId=200285, objectId=7fde2002858b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fde2002858b, replyNumber=0, likeNumber=93, createdTime=2020-09-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fde2002858b, moduleTitle=康宁杰瑞PD-L1/CTLA-4双特异性抗体获FDA孤儿药资格认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fde2002858b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255084, encodeId=277912550849c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1单抗Imfinzi在日本获批，治疗广泛期小细胞肺癌, objectType=article, longId=199855, objectId=787719985534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=787719985534, replyNumber=0, likeNumber=74, createdTime=2020-08-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=787719985534, moduleTitle=PD-L1单抗Imfinzi在日本获批，治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=787719985534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255083, encodeId=940a12550835d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=抗CD47 / PD-L1双特异性抗体临床试验：中国首例患者已入组, objectType=article, longId=198679, objectId=2c651986e9a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c651986e9a6, replyNumber=0, likeNumber=91, createdTime=2020-08-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c651986e9a6, moduleTitle=抗CD47 / PD-L1双特异性抗体临床试验：中国首例患者已入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c651986e9a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255082, encodeId=4f681255082e4, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, objectType=article, longId=198563, objectId=ec5d198563ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec5d198563ab, replyNumber=0, likeNumber=70, createdTime=2020-08-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec5d198563ab, moduleTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec5d198563ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255081, encodeId=927512550812d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法, objectType=article, longId=198551, objectId=2cb719855145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cb719855145, replyNumber=0, likeNumber=60, createdTime=2020-08-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cb719855145, moduleTitle=PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cb719855145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255080, encodeId=089f1255080ac, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Clini Cancer Res：PD-L1表达与三阴性乳腺癌新辅助化疗预后的相关性, objectType=article, longId=198067, objectId=a92519806e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a92519806e26, replyNumber=0, likeNumber=54, createdTime=2020-07-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a92519806e26, moduleTitle=Clini Cancer Res：PD-L1表达与三阴性乳腺癌新辅助化疗预后的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a92519806e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255079, encodeId=0de312550e91a, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=抗Trop-2的ADC药物Trodelvy联合PD-L1单抗Tecentriq：治疗尿道上皮癌和非小细胞肺癌, objectType=article, longId=197602, objectId=cbf019e602e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbf019e602e0, replyNumber=0, likeNumber=59, createdTime=2020-07-17, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbf019e602e0, moduleTitle=抗Trop-2的ADC药物Trodelvy联合PD-L1单抗Tecentriq：治疗尿道上皮癌和非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbf019e602e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255078, encodeId=49b012550e8b8, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, objectType=article, longId=197518, objectId=29ba19e518a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29ba19e518a8, replyNumber=0, likeNumber=64, createdTime=2020-07-16, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29ba19e518a8, moduleTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29ba19e518a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255077, encodeId=489b12550e735, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Brit J Cancer：抗PD-L1免疫治疗和放疗联用对肿瘤免疫微环境的影响 , objectType=article, longId=197412, objectId=512719e41250, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=512719e41250, replyNumber=0, likeNumber=74, createdTime=2020-07-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=512719e41250, moduleTitle=Brit J Cancer：抗PD-L1免疫治疗和放疗联用对肿瘤免疫微环境的影响 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=512719e41250)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nat Med：不适合顺铂治疗的高风险尿路上皮癌患者的新辅助PD-L1加CTLA-4阻断疗法

2020-11-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者

2020-10-31

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nat Cell Biol：到底是促癌还是抑癌？PD-L1还有不为人知的一面

2020-10-17

hb2008ye (审核中...)

前往app查看评论内容

#PD-L1#

Nat Commun：研究定义了PD-L1阴性ER阳性乳腺癌患者的新型免疫特征

2020-10-07

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

辉瑞投资基石药业2亿美元，获得PD-L1大陆**商业权利

2020-10-02

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet oncol：PD-L1抑制剂Durvalumab±曲美单抗治疗转移性尿路上皮癌

2020-09-25

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

T药+白蛋白紫杉醇一线治疗三阴乳腺癌：PD-L1阳性人群OS获益显著，亚洲人群不佳

2020-09-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Br J Cancer：FOXP3和PD-L1或可成为化生性乳腺癌的潜在治疗靶标

2020-09-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nat Cell Biol：不仅仅是免疫检查点，Nature子刊揭示PD-L1在肿瘤焦亡中的新机制

2020-09-22

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

皮下注射PD-L1在中国申报上市，拟优先审评

2020-09-21

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nat Commun：抗GARP:TGF-β1单抗能克服PD-1/PD-L1抑制剂耐药性

2020-09-18

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

康宁杰瑞PD-L1/CTLA-4双特异性抗体获FDA孤儿药资格认定

2020-09-06

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1单抗Imfinzi在日本获批，治疗广泛期小细胞肺癌

2020-08-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

抗CD47 / PD-L1双特异性抗体临床试验：中国首例患者已入组

2020-08-05

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤

2020-08-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法

2020-08-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Clini Cancer Res：PD-L1表达与三阴性乳腺癌新辅助化疗预后的相关性

2020-07-28

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

抗Trop-2的ADC药物Trodelvy联合PD-L1单抗Tecentriq：治疗尿道上皮癌和非小细胞肺癌

2020-07-17

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败

2020-07-16

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Brit J Cancer：抗PD-L1免疫治疗和放疗联用对肿瘤免疫微环境的影响

2020-07-14

科室
- - 订阅+
  - 更多科室
工具
服务